These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. Adam RD; Coriu D; Jercan A; Bădeliţă S; Popescu BA; Damy T; Jurcuţ R ESC Heart Fail; 2021 Aug; 8(4):2380-2396. PubMed ID: 34089308 [TBL] [Abstract][Full Text] [Related]
5. Glycosylation of Serum Clusterin in Wild-Type Transthyretin-Associated (ATTRwt) Amyloidosis: A Study of Disease-Associated Compositional Features Using Mass Spectrometry Analyses. Torres-Arancivia CM; Chang D; Hackett WE; Zaia J; Connors LH Biochemistry; 2020 Nov; 59(45):4367-4378. PubMed ID: 33141553 [TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition. Biolo A; Ramamurthy S; Connors LH; O'Hara CJ; Meier-Ewert HK; Soo Hoo PT; Sawyer DB; Seldin DC; Sam F Circ Heart Fail; 2008 Nov; 1(4):249-57. PubMed ID: 19808299 [TBL] [Abstract][Full Text] [Related]
7. The transthyretin amyloidoses: advances in therapy. Dubrey S; Ackermann E; Gillmore J Postgrad Med J; 2015 Aug; 91(1078):439-48. PubMed ID: 26048914 [TBL] [Abstract][Full Text] [Related]
8. Analysis of the TTR gene in the investigation of amyloidosis: A 25-year single UK center experience. Rowczenio D; Quarta CC; Fontana M; Whelan CJ; Martinez-Naharro A; Trojer H; Baginska A; Ferguson SM; Gilbertson J; Rezk T; Sachchithanantham S; Mahmood S; Manwani R; Sharpley F; Wechalekar AD; Hawkins PN; Gillmore JD; Lachmann HJ Hum Mutat; 2019 Jan; 40(1):90-96. PubMed ID: 30328212 [TBL] [Abstract][Full Text] [Related]
14. Non-Val30Met mutation, septal hypertrophy, and cardiac denervation in patients with mutant transthyretin amyloidosis. Hirakawa K; Takashio S; Marume K; Yamamoto M; Hanatani S; Yamamoto E; Sakamoto K; Izumiya Y; Kaikita K; Oda S; Utsunomiya D; Shiraishi S; Ueda M; Yamashita T; Yamashita Y; Ando Y; Tsujita K ESC Heart Fail; 2019 Feb; 6(1):122-130. PubMed ID: 30284755 [TBL] [Abstract][Full Text] [Related]
15. Wild type transthyretin cardiac amiloidozis as a rare and overlooked underlying etiology in a patient with heart failure with preserved ejection fraction and left ventricular hypertrophy. Murat S; Çavuşoğlu Y; Ak Sivrikoz İ Turk Kardiyol Dern Ars; 2021 Oct; 49(7):579-584. PubMed ID: 34623301 [TBL] [Abstract][Full Text] [Related]